Global Gastrointestinal Cancer Market Size Projected to Reach $42.45 Billion During the Forecast Period

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Gastrointestinal Cancer Market Over The Five-Year Period 2025–2029?

The gastrointestinal cancer market size has experienced swift expansion in recent years. It is anticipated to increase from $24.09 billion in 2024 to $27.05 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.3%. The historical growth of this market is attributable to the increasing incidence of gastrointestinal cancers, rising consumption of tobacco and alcohol, an expanding elderly demographic, inadequate dietary practices, and continuous developments in oncology diagnostics and therapies.

Significant expansion is anticipated for the gastrointestinal cancer market size over the coming years. This market is projected to reach $42.45 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 11.9%. Factors contributing to this growth during the forecast period include the increasing uptake of biomarker-driven treatments, greater awareness regarding early detection, the expansion of healthcare infrastructure, governmental efforts in cancer care, and an increased emphasis on less invasive medical procedures. Key trends expected within the forecast timeframe encompass technological improvements in diagnostic instrumentation, novel developments in targeted treatments, advancements in immunotherapy, the expanding application of artificial intelligence in treating cancer, and continuous investigative efforts in precision oncology.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

Which Drivers Are Shaping The Gastrointestinal Cancer Industry’s Market Share?

The increasing acceptance and use of targeted therapies are anticipated to boost the expansion of the gastrointestinal cancer market in the future. These therapies work by precisely inhibiting the multiplication of cancer cells, focusing on particular molecular targets while minimizing damage to healthy cells. Specifically, they are engineered to target distinct molecular pathways or genetic alterations that fuel disease progression, particularly in cancerous conditions. In contrast to conventional treatments such as chemotherapy, which indiscriminately attack both healthy and cancerous cells, targeted therapies concentrate on the specific attributes of an individual patient’s illness. For gastrointestinal (GI) cancer, these therapies operate by influencing particular genes or proteins responsible for tumor development, thereby providing a more accurate and potent treatment approach. This leads to improved patient results and a reduction in adverse effects compared to standard chemotherapy. An example illustrating this trend is that in July 2023, data from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, indicated that there were 247 gene therapies in Phase II at the close of quarter one (Q1) 2023, a figure that increased by 5% to 260 by the end of quarter two (Q2). Consequently, the increasing adoption of targeted therapies is propelling the expansion of the gastrointestinal cancer market.

How Is The Gastrointestinal Cancer Market Segmented?

The gastrointestinal cancer market covered in this report is segmented –

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

Which Ongoing Trends Are Expected To Shape The Gastrointestinal Cancer Market Outlook?

Leading companies in the gastrointestinal cancer market are focusing on developing advanced solutions, such as monoclonal antibody treatment, to enhance patient survival rates and reduce side effects related to treatment. Monoclonal antibody treatment functions by employing laboratory-created antibodies that precisely identify and bind to cancer cells, aiding the immune system in targeting and eliminating them. For example, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) for use in combination with fluoropyrimidine- and platinum-containing chemotherapy, following its approval from the European Commission. This medication is a first-line treatment for adults suffering from locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma where tumors express claudin 18.2 (CLDN18.2). With this approval, VYLOY becomes the first and sole therapy available in the European Union that targets CLDN18.2, a biomarker present in approximately 38% of these patients, a finding supported by positive clinical trial data from the SPOTLIGHT and GLOW studies.

Which Global Market Leaders Are Shaping The Future Of The Gastrointestinal Cancer Sector?

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

What Are The Key Regional Factors Influencing The Gastrointestinal Cancer Market Growth?

North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gastrointestinal Cancer Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Cancer Market 2025, By The Business Research Company

Intestine Cancer Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Colorectal Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795